Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioKALA +0.44%21 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates KALA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, Kala Bio ranks worse than 96.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kala Bio's Debt-to-Equity or its related term are showing as below:
KALA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -44.09 Med: 0.98 Max: 5.67
Current: 3.31
During the past 11 years, the highest Debt-to-Equity Ratio of Kala Bio was 5.67. The lowest was -44.09. And the median was 0.98.
KALA's Debt-to-Equity is ranked worse than 96.44% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs KALA: 3.31
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kala Bio Debt-to-Equity Related Terms
Kala Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kala Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KALA vs GDTC, GTBP, INAB: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kala Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kala Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (KALA) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kala Bio and its competitors. According to the industry distribution chart, Kala Bio ranks #922 out of 956 companies in the Biotechnology industry, placing it in the top 96.4%.
Is Kala Bio's Debt-to-Equity too high?
Kala Bio's current Debt-to-Equity is 0.00. Based on the distribution chart, Kala Bio ranks #922 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kala Bio has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's Debt-to-Equity compare to GDTC and GTBP?
According to the Biotechnology industry distribution chart, Kala Bio ranks #922 out of 956 companies for Debt-to-Equity. This places Kala Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kala Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (KALA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Kala Bio's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kala Bio (KALA), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
21GF Score
Get the complete analysis for KALA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KALA has been successfully added to your 
